AEMD Company Profile and Key Details

AEMD has shown mixed momentum, gaining 13.45% over the past week and -50.29% over the past quarter, though year-to-date performance is down -2.53%. Short-term trend indicators are bullishly aligned (SMA20 -7.25%, SMA50 -20.39%, SMA200 -79.69%). The stock’s 14-day RSI is 36.43 (weak momentum), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -95.83% below its high and over 7.67% above its low. Average 10-day trading volume of 72.37 thousand shares is below the 3-month average of 138.78 thousand, indicating normal recent market interest.

Aethlon Medical, Inc. has 526.71 thousand shares outstanding. The public float is 470.28 thousand shares, elevated short interest at 8.70% of float. This equals 45.69 thousand shares. The short ratio is 1.06 days. Institutional investors hold 6.13% of the float. Insiders own 5.15%. BROENNIMAN EDWARD G holds 282.17 thousand shares, BARRY FRANKLYN S JR has 106.59 thousand shares and Shah Chetan has 16.64 thousand shares.

Aethlon Medical, Inc. generated EPS of -$45.83 over the past year. Five-year average earnings growth is 43.53%. Wall Street analysts project EPS growth of 82.0% annually over the next five years. The latest quarter delivered EPS of $4.08. The next quarter is forecast at -$2.01. Next year's EPS is expected at -$5.78. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $1.50 to $1.50. The high target offers -50.66% upside. The low target suggests -50.66% downside. The mean target is $1.50. This offers -50.66% upside. Aethlon Medical, Inc. earnings surprise history is a mixed track record. The quarter that ended June 10, 2026, missed forecasts by -288.4%. The prior quarter beat by 21.89%. Over the last six quarters, Apple has recorded several small beats. These include -40.91% in February 12, 2025.

Aethlon Medical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.96. This means the shares are trading below this model’s fair value.

Aethlon Medical, Inc. (NASDAQ:AEMD) closed at $2.95 USD, losing -$0.09 (-2.96%) from the previous close of $3.04. The stock is currently mid-range between its 52-week high and low $2.65 and $137.00. With a market capitalization of about $1.55 million, Aethlon Medical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.44). Key stats such as the average daily volume over the past year has been around 141.79 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Aethlon Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO James Frakes, the company employs approximately 9 people and listed since March 04, 1999. Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States.

Aethlon Medical, Inc. trades at a P/E ratio of -0.18, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.77 suggesting the stock is closer to book value. The P/FCF stands at -0.22, also above market averages.

Aethlon Medical, Inc. (NASDAQ:AEMD) shares are flat -2.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aethlon Medical, Inc. trading at a premium to the broader market with a P/E of -0.18. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $5.43, suggesting 78.62% upside. Our AI forecast model points to short-term weakness (-12.17% over two weeks), a medium-term fall (-71.38% over three months), and a longer-term loss (-76.64% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Aethlon Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.17%, with price expected at $2.67 by August 26, 2026, within a range of $2.18 to $3.16 3-Month Outlook: Projected fall of -71.38%, reaching $0.87 by November 10, 2026, with a range of $0.00 to $3.80. 1-Year Outlook: Projected loss of -76.64%, with price at $0.71 by August 12, 2027, within a range of $0.00 to $0.00.